YKL-GB

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameYKL-GB

Drug Alias NameGM-CSF/B7-1-expressing oncolytic adenovirus (Yonsei University College of Medicine)oncolytic adenovirus therapy expressing GM-CSF + CD28 costimulator (Yonsei University College of Medicine)YKL-GB

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsGranulocyte-macrophage colony-stimulating factor receptor stimulants

TargetsT-cell-specific surface glycoprotein CD28Granulocyte-macrophage colony-stimulating factor receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesYonsei University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesYonsei University

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A